Skip to main content

Peer Review reports

From: Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)

Original Submission
11 Nov 2019 Submitted Original manuscript
2 Jan 2020 Reviewed Reviewer Report - Kirsty Loudon
30 Jan 2020 Author responded Author comments - Ruth Nabisere
Resubmission - Version 2
30 Jan 2020 Submitted Manuscript version 2
1 Feb 2020 Editorially accepted
13 Feb 2020 Article published 10.1186/s13063-020-4132-7

You can find further information about peer review here.

Back to article page